ArticleThe Journal of antimicrobial chemotherapy2007
The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins.
Article in The Journal of antimicrobial chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Chemistry and biology of specialized metabolites produced byNatural product reports · 2024Review
- Review
- Sensing the interactions between carbohydrate-binding agents andJournal of biomolecular structure & dynamics · 2022Article
- Antiviral Activity of Medicinal Plants against Human Coronavirus: a systematic scoping review of and experimentations.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- Lectins and lectibodies: potential promising antiviral agents.Cellular & molecular biology letters · 2022Review
- Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection.Science advances · 2021Article
- An Exploratory Review of Potential Adjunct Therapies for the Treatment of Coronavirus Infections.Journal of chiropractic medicine · 2021Review
- Feline Coronavirus Antivirals: A Review.Pathogens (Basel, Switzerland) · 2021Review
- Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.Antiviral research · 2021Article
- Review
- A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov.Molecules (Basel, Switzerland) · 2021Review
- Algae-Derived Bioactive Molecules for the Potential Treatment of SARS-CoV-2.Molecules (Basel, Switzerland) · 2021Review
- Antiviral activity of bioactive phytocompounds against coronavirus: An update.Journal of virological methods · 2021Review
- Article
- Potential anti-influenza effective plants used in Turkish folk medicine: A review.Journal of ethnopharmacology · 2021Review
- Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus.Biomedicines · 2020Review
- Potential Therapeutic Options for COVID-19.Infectious microbes & diseases · 2020Review
- Article
- Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.Antiviral research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMany enveloped viruses carry carbohydrate-containing proteins on their surface. These glycoproteins are key to the infection process as they are mediators of the receptor binding and membrane fusion of the virion with the host cell. Therefore, they are attractive therapeutic targets for the development of novel antiviral therapies. Recently, carbohydrate-binding agents (CBA) were shown to possess antiviral activity towards coronaviruses. The current study further elucidates the inhibitory mode of action of CBA.
methodsDifferent strains of two coronaviruses, mouse hepatitis virus and feline infectious peritonitis virus, were exposed to CBA: the plant lectins Galanthus nivalis agglutinin, Hippeastrum hybrid agglutinin and Urtica dioica agglutinin (UDA) and the non-peptidic mannose-binding antibiotic pradimicin A. RESULTS AND
conclusionsOur results indicate that CBA target the two glycosylated envelope glycoproteins, the spike (S) and membrane (M) protein, of mouse hepatitis virus and feline infectious peritonitis virus. Furthermore, CBA did not inhibit virus-cell attachment, but rather affected virus entry at a post-binding stage. The sensitivity of coronaviruses towards CBA was shown to be dependent on the processing of the N-linked carbohydrates. Inhibition of mannosidases in host cells rendered the progeny viruses more sensitive to the mannose-binding agents and even to the N-acetylglucosamine-binding UDA. In addition, inhibition of coronaviruses was shown to be dependent on the cell-type used to grow the virus stocks. All together, these results show that CBA exhibit promising capabilities to inhibit coronavirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.